Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Ho GY, Vandenberg CJ, Lim R, Christie EL, Garsed DW, Lieschke E, Nesic K, Kondrashova O, Ratnayake G, Radke M, Penington JS, Carmagnac A, Heong V, Kyran EL, Zhang F, Traficante N; Australian Ovarian Cancer Study; Huang R, Dobrovic A, Swisher EM, McNally O, Kee D, Wakefield MJ, Papenfuss AT, Bowtell DDL, Barker HE, Scott CL. Ho GY, et al. Among authors: wakefield mj. Ther Adv Med Oncol. 2023 Nov 22;15:17588359231208674. doi: 10.1177/17588359231208674. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38028140 Free PMC article.
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Marks ZRC, Campbell NK, Mangan NE, Vandenberg CJ, Gearing LJ, Matthews AY, Gould JA, Tate MD, Wray-McCann G, Ying L, Rosli S, Brockwell N, Parker BS, Lim SS, Bilandzic M, Christie EL, Stephens AN, de Geus E, Wakefield MJ, Ho GY, McNally O; Australian Ovarian Cancer Study; McNeish IA, Bowtell DDL, de Weerd NA, Scott CL, Bourke NM, Hertzog PJ. Marks ZRC, et al. Among authors: wakefield mj. Nature. 2023 Aug;620(7976):1063-1070. doi: 10.1038/s41586-023-06421-w. Epub 2023 Aug 16. Nature. 2023. PMID: 37587335
Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G, Vandenberg CJ, Nesic K, Ratnayake G, Zhu W, Vissers JHA, Bedő J, Penington J, Wakefield MJ, Kee D, Carmagnac A, Lim R, Shield-Artin K, Milesi B, Lobley A, Kyran EL, O'Grady E, Tram J, Zhou W, Nugawela D, Stewart KP, Caldwell R, Papadopoulos L, Ng AP, Dobrovic A, Fox SB, McNally O, Power JD, Meniawy T, Tan TH, Collins IM, Klein O, Barnett S, Olesen I, Hamilton A, Hofmann O, Grimmond S, Papenfuss AT, Scott CL, Barker HE. Dall G, et al. Among authors: wakefield mj. J Exp Clin Cancer Res. 2023 May 4;42(1):112. doi: 10.1186/s13046-023-02687-0. J Exp Clin Cancer Res. 2023. PMID: 37143137 Free PMC article.
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K, Krais JJ, Vandenberg CJ, Wang Y, Patel P, Cai KQ, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, Swisher EM, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. Nesic K, et al. Among authors: wakefield mj. medRxiv [Preprint]. 2023 Aug 28:2023.03.20.23287465. doi: 10.1101/2023.03.20.23287465. medRxiv. 2023. PMID: 36993400 Free PMC article. Preprint.
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Ho GY, Kyran EL, Bedo J, Wakefield MJ, Ennis DP, Mirza HB, Vandenberg CJ, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey UM, Dowson S, Roxburgh P, Glasspool RM, Bryson G, Biankin AV; Scottish Genomes Partnership; Cooke SL, Ratnayake G, McNally O, Traficante N; Australian Ovarian Cancer Study12,13; DeFazio A, Weroha SJ, Bowtell DD, McNeish IA, Papenfuss AT, Scott CL, Barker HE. Ho GY, et al. Among authors: wakefield mj. Cancer Res. 2022 Dec 2;82(23):4457-4473. doi: 10.1158/0008-5472.CAN-21-4012. Cancer Res. 2022. PMID: 36206301 Free PMC article.
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL. Nesic K, et al. Among authors: wakefield mj. Cancer Res. 2021 Sep 15;81(18):4709-4722. doi: 10.1158/0008-5472.CAN-21-0774. Epub 2021 Jul 28. Cancer Res. 2021. PMID: 34321239
Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, Swisher EM, Li H, Weroha SJ, Kaufmann SH. Hurley RM, et al. Among authors: wakefield mj. NAR Cancer. 2021 Jul 9;3(3):zcab028. doi: 10.1093/narcan/zcab028. eCollection 2021 Sep. NAR Cancer. 2021. PMID: 34316715 Free PMC article.
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors.
Grohmann C, Walker F, Devlin M, Luo MX, Chüeh AC, Doherty J, Vaillant F, Ho GY, Wakefield MJ, Weeden CE, Kamili A, Murray J, Po'uha ST, Weinstock J, Kane SR, Faux MC, Broekhuizen E, Zheng Y, Shield-Artin K, Kershaw NJ, Tan CW, Witchard HM, Ebert G, Charman SA, Street I, Kavallaris M, Haber M, Fletcher JI, Asselin-Labat ML, Scott CL, Visvader JE, Lindeman GJ, Watson KG, Burgess AW, Lessene G. Grohmann C, et al. Among authors: wakefield mj. Cell Death Dis. 2021 Mar 12;12(3):268. doi: 10.1038/s41419-020-03269-0. Cell Death Dis. 2021. PMID: 33712556 Free PMC article.
74 results